Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2.4% decrease for the ...

Interim data from Phase 1 with single and multiple ascending doses show no safety signals and a generally favorable tolerability profile of ...

Remedy Cell, a clinical-stage biopharmaceutical company focused on the development of proprietary cell-derived therapies for fibrotic diseases, today announces the initiation of "a partially-blinded ...

A hybrid model combining LM, GA, and BP neural networks improves TCM's diagnostic accuracy for IPF, achieving 81.22% ...

AI models suggest IPF is a dysregulation of aging, not just accelerated aging, with unique gene expression patterns. Key pathways in IPF and aging include TGF-β signaling, oxidative stress, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Prior to this trial, CS014 had positive outcomes in an ...

Please provide your email address to receive an email when new articles are posted on . Saracatinib appeared to be “equal or superior” in stopping fibrotic responses compared with two FDA-approved ...

Long-held dogma says lung fibrosis in diseases like idiopathic pulmonary fibrosis, or IPF, results from recurrent injury to alveolar epithelium that is followed by dysregulated repair. Research at the ...

International Personal Finance ( ($GB:IPF) ) has shared an announcement. International Personal Finance Plc (IPF) has announced an extension of ...

International Personal Finance said the U.K. takeover panel agreed to extend the deadline for BasePoint Capital to announce a firm intention to make an offer. IPF and U.S. peer BasePoint have been in ...

British lender International Personal Finance said on Monday it has agreed to a 543 million-pound ($732.51 million) takeover ...